Suppr超能文献

重新编程功能失调的 CD8 T 细胞对检查点阻断的反应性。

Reprogramming responsiveness to checkpoint blockade in dysfunctional CD8 T cells.

机构信息

Department of Microbiology and Immunology, University of Minnesota, Minneapolis, MN 55455.

Center for Immunology, University of Minnesota, Minneapolis, MN 55455.

出版信息

Proc Natl Acad Sci U S A. 2019 Feb 12;116(7):2640-2645. doi: 10.1073/pnas.1810326116. Epub 2019 Jan 24.

Abstract

Established T cell dysfunction is a barrier to antitumor responses, and checkpoint blockade presumably reverses this. Many patients fail to respond to treatment and/or develop autoimmune adverse events. The underlying reason for T cell responsiveness remains elusive. Here, we show that susceptibility to checkpoint blockade is dependent on the activation status of T cells. Newly activated self-specific CD8 T cells respond to checkpoint blockade and cause autoimmunity, which is mitigated by inhibiting the mechanistic target of rapamycin. However, once tolerance is established, self-specific CD8 T cells display a gene signature comparable to tumor-specific CD8 T cells in a fixed state of dysfunction. Tolerant self-specific CD8 T cells do not respond to single or combinatorial dosing of anti-CTLA4, anti-PD-L1, anti-PD-1, anti-LAG-3, and/or anti-TIM-3. Despite this, T cell responsiveness can be induced by vaccination with cognate antigen, which alters the previously fixed transcriptional signature and increases antigen-sensing machinery. Antigenic reeducation of tolerant T cells synergizes with checkpoint blockade to generate functional CD8 T cells, which eliminate tumors without concomitant autoimmunity and are transcriptionally distinct from classic effector T cells. These data demonstrate that responses to checkpoint blockade are dependent on the activation state of a T cell and show that checkpoint blockade-insensitive CD8 T cells can be induced to respond to checkpoint blockade with robust antigenic stimulation to participate in tumor control.

摘要

已建立的 T 细胞功能障碍是抗肿瘤反应的障碍,而检查点阻断剂大概可以逆转这种障碍。许多患者对治疗无反应和/或出现自身免疫不良反应。T 细胞反应性的根本原因仍难以捉摸。在这里,我们表明,检查点阻断剂的敏感性取决于 T 细胞的激活状态。新激活的自身特异性 CD8 T 细胞对检查点阻断剂有反应并引起自身免疫,而雷帕霉素的作用机制靶点可以减轻这种反应。然而,一旦建立了耐受,自身特异性 CD8 T 细胞就会表现出与处于固定功能障碍状态的肿瘤特异性 CD8 T 细胞相当的基因特征。耐受的自身特异性 CD8 T 细胞对单剂量或联合使用抗 CTLA4、抗 PD-L1、抗 PD-1、抗 LAG-3 和/或抗 TIM-3 没有反应。尽管如此,用同源抗原进行疫苗接种可以诱导 T 细胞反应性,这会改变之前固定的转录特征,并增加抗原感应机制。耐受 T 细胞的抗原重新教育与检查点阻断协同作用,产生功能性 CD8 T 细胞,这些细胞在没有伴随自身免疫的情况下消除肿瘤,并且在转录上与经典效应 T 细胞不同。这些数据表明,对检查点阻断剂的反应取决于 T 细胞的激活状态,并表明可以通过强烈的抗原刺激诱导对检查点阻断剂无反应的 CD8 T 细胞对检查点阻断剂产生反应,以参与肿瘤控制。

相似文献

1
Reprogramming responsiveness to checkpoint blockade in dysfunctional CD8 T cells.重新编程功能失调的 CD8 T 细胞对检查点阻断的反应性。
Proc Natl Acad Sci U S A. 2019 Feb 12;116(7):2640-2645. doi: 10.1073/pnas.1810326116. Epub 2019 Jan 24.

引用本文的文献

4
PD-1 maintains CD8 T cell tolerance towards cutaneous neoantigens.PD-1 维持 CD8 T 细胞对皮肤新生抗原的耐受。
Nature. 2023 Jul;619(7968):151-159. doi: 10.1038/s41586-023-06217-y. Epub 2023 Jun 21.

本文引用的文献

9
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.纳武单抗与依维莫司治疗晚期肾细胞癌的比较
N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25.
10
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.错配修复缺陷肿瘤中的程序性死亡受体-1阻断
N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验